Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4365% % -18%
Debt-to-equity 4.4% % -9.1%
Return On Equity -12% % -25%
Return On Assets -11% % -26%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,831,656 shares 2.9%
Common Stock, Shares, Outstanding 60,384,283 shares 2.2%
Entity Public Float $1,100,000,000 USD -15%
Common Stock, Value, Issued $60,000 USD 1.7%
Weighted Average Number of Shares Outstanding, Basic 61,966,999 shares 15%
Weighted Average Number of Shares Outstanding, Diluted 61,966,999 shares 15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $125,896,000 USD 84%
General and Administrative Expense $41,771,000 USD 1.8%
Operating Income (Loss) $157,667,000 USD -60%
Nonoperating Income (Expense) $44,042,000 USD 48%
Net Income (Loss) Attributable to Parent $113,625,000 USD -65%
Earnings Per Share, Basic -1.83 USD/shares -43%
Earnings Per Share, Diluted -1.83 USD/shares -43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $52,334,000 USD -88%
Accounts Receivable, after Allowance for Credit Loss, Current $7,500,000 USD
Assets, Current $975,887,000 USD -5.6%
Property, Plant and Equipment, Net $3,852,000 USD -21%
Operating Lease, Right-of-Use Asset $18,402,000 USD -4.6%
Other Assets, Noncurrent $2,608,000 USD -9.6%
Assets $1,001,565,000 USD -5.6%
Accounts Payable, Current $4,971,000 USD 23%
Employee-related Liabilities, Current $4,590,000 USD 0.53%
Accrued Liabilities, Current $17,633,000 USD 51%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $24,997,000 USD 43%
Operating Lease, Liability, Noncurrent $19,746,000 USD -7.2%
Liabilities $44,743,000 USD 16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,316,000 USD 100%
Retained Earnings (Accumulated Deficit) $351,382,000 USD -48%
Stockholders' Equity Attributable to Parent $956,822,000 USD -6.4%
Liabilities and Equity $1,001,565,000 USD -5.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $17,024,000 USD -15%
Net Cash Provided by (Used in) Financing Activities $554,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $340,392,000 USD -199%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 60,384,283 shares 2.2%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $90,014,000 USD 35%
Deferred Tax Assets, Gross $95,971,000 USD 31%
Operating Lease, Liability $22,139,000 USD -3.8%
Depreciation $519,000 USD -2.4%
Payments to Acquire Property, Plant, and Equipment $371,000 USD 88%
Lessee, Operating Lease, Liability, to be Paid $28,965,000 USD -8.2%
Property, Plant and Equipment, Gross $10,819,000 USD 10%
Operating Lease, Liability, Current $2,393,000 USD 37%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,173,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,052,000 USD 16%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6,826,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,868,000 USD 4%
Deferred Tax Assets, Operating Loss Carryforwards $42,022,000 USD 64%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $5,480,000 USD 36%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,945,000 USD 3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $5,957,000 USD -11%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%